Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy

Lancet

Volumn 358, Issue 9295, 2001, Pages 1760-1765

  Polis, M A ^a   Sidorov, I A ^b   Yoder, C ^c   Jankelevich, S ^a   Metcalf, J ^a   Mueller, B U ^d   Dimitrov, M A ^e   Pizzo, P ^f   Yarchoan, R ^g   Dimitrov, D S ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; LONG TERM CARE; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCTION; TREATMENT OUTCOME;

EID: 0035944856     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06802-7     Document Type: Article

References (25)

1. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
2. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
3. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
4. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
5. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response
6. Predictors of optimal virological response to potent antiretroviral therapy
7. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load
8. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy
9. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy
10. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: Relationships to host factors, cellular restoration, and virologic end points
11. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 rna levels following nelfinavir monotherapy
12. A phase I/II study of the protease inhibitor indinavir in children with HIV infection
13. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection
14. The jackknife: A review
15. Decay characteristics of HIV-1-infected compartments during combination therapy
16. Ongoing HIV dissemination during HAART
17. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy
18. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment
19. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
20. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
21. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads
22. HIV infection: How effective is drug combination treatment?
23. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations?
24. A model of HIV-1 pathogenesis that includes an intracellular delay